COMPANY PROFILE

Acologix

Explore full profile

Biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases

Hayward, United StatesFounded 1992Biotech & Life Sciences

Valuation $100–250M Last recorded · 2006

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Acologix

Acologix, Inc. is a biopharmaceutical company that identifies, develops, and commercializes therapeutic compounds for the treatment of osteo-renal diseases. The company's focus is on therapies for diseases related to bone and mineral metabolism.

Acologix's primary area of expertise lies in mineral metabolism, and it leverages this to develop biopharmaceuticals. The company's business model revolves around the entire lifecycle of drug development, from identification of promising compounds to their eventual commercialization. The target market for Acologix's products are patients suffering from osteo-renal conditions, and the company operates within the broader biopharmaceutical and healthcare industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1992
Headquarters: Hayward, United States
Employees: 8
Open positions: None listed
Dealroom signal: 20.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Feb 2006	$30M	$120M	Undisclosed	—
SERIES BOther financing	May 2004	$40M	$160M	SMBC Venture Capital · JAIC America · Tokio Marine	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Acologix website traffic

Latest recorded traffic for Acologix is 50 monthly website visits. Acologix's team grew 0% over the past year.

Latest monthly visits50 1-year team growth0%

Monthly website visitsApr 2016–Jan 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational